Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase‐associated pancreatitis
- 29 April 2009
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 53 (2), 162-167
- https://doi.org/10.1002/pbc.22076
Abstract
Background Asparaginase, an agent used in the treatment of acute lymphoblastic leukemia (ALL), is associated with the development of pancreatitis. The clinical course and long‐term outcome of patients experiencing this complication has not been extensively detailed. Procedure We reviewed the clinical course for all children with ALL diagnosed with pancreatitis at the Dana‐Farber Cancer Institute/Children's Hospital Boston between 1987 and 2003. The outcome of these patients was compared with that of patients with ALL who did not experience pancreatitis. Results Twenty‐eight of 403 children (7%) were diagnosed with pancreatitis. Patients 10–18 years old at diagnosis had 2.4 times the risk of developing pancreatitis compared with younger patients. Pancreatitis typically occurred early in the course of therapy (median 4 weeks after first dose of asparaginase). Ninety‐three percent of affected patients were hospitalized and 57% received parenteral nutrition. No patient developed chronic sequelae or died as a result of pancreatitis. Sixteen (57%) patients were re‐treated with asparaginase, 10 of whom had another episode of pancreatitis. No significant differences in event‐free survival were observed when comparing patients with and without a history of pancreatitis. Conclusion Asparaginase‐associated pancreatitis was more common in older children, and caused significant acute morbidity. It tended to occur after the first few doses of asparaginase, suggesting a predisposition to this complication rather than a cumulative drug effect. Re‐treatment with asparaginase after an episode of pancreatitis was associated with a high risk of recurrent pancreatitis. Pediatr Blood Cancer 2009;53:162–167.Keywords
Funding Information
- National Cancer Institute (5P01CA68484)
This publication has 30 references indexed in Scilit:
- Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemiaBlood, 2006
- Treatment of Childhood Acute Lymphoblastic Leukemia: Results of Dana-Farber ALL Consortium Protocol 87-01Journal of Clinical Oncology, 2002
- Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01Blood, 2001
- Hypercoagulability during l‐asparaginase treatment: the effect of antithrombin III supplementation in vivoBritish Journal of Haematology, 1990
- Four-Agent Induction and Intensive Asparaginase Therapy for Treatment of Childhood Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 1986
- Optimal use of L‐asparaginase (NSC‐109229) in acute lymphocytic leukemiaMedical and Pediatric Oncology, 1977
- Evaluation of dose and schedule of L-asparaginase in multidrug therapy of childhood leukemiaMedical and Pediatric Oncology, 1976
- Diabetes mellitus secondary to l-asparaginase therapyThe Journal of Pediatrics, 1972
- STUDIES ON THE MECHANISM OF TUMOR INHIBITION BY L-ASPARAGINASEThe Journal of Experimental Medicine, 1968
- Asparagine Synthetase Activity of Mouse LeukemiasScience, 1968